#### 1

## 1 Triangulating Evidence for Antihypertensive Drug Class Efficacy on

## 2 Cardiovascular and Metabolic Outcomes Using Mendelian Randomisation and

- 3 Colocalisation
- 4 Nhu Ngoc Le<sup>1</sup>, Tran Quoc Bao Tran<sup>1</sup>, John McClure<sup>1</sup>, Dipender Gill<sup>2</sup>, Sandosh
- 5 Padmanabhan<sup>1</sup>

<sup>1</sup> BHF Cardiovascular Research Center, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow G12 8TA, UK

<sup>2</sup> Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1PG, UK

### **Corresponding author:**

Prof. Sandosh Padmanabhan

Sandosh.Padmanabhan@glasgow.ac.uk

BHF Cardiovascular Research Center, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow G12 8TA, UK

Total word count: 7237 words (Main text: 4369 words)

Abstract word count: 306 words

2

## 6 Abstract

### 7 Background

8 Current hypertension treatment guidelines typically recommend a standardised 9 approach, which may not account for the inter-individual variability in blood pressure 10 (BP) response or the complex causation of hypertension. This study aims to 11 investigate the heterogeneity of responses to a broad range of antihypertensive 12 drugs across various cardiometabolic and renal outcomes.

#### 13 Methods

14 This study employed an integrative approach combining Mendelian randomisation 15 (MR), summary-based MR (SMR), and colocalisation analyses to investigate the impact of BP lowering and the efficacy of seventeen antihypertensive drug classes 16 on the risk of coronary artery disease (CAD), myocardial infarction (MI), atrial 17 18 fibrillation (AF), heart failure (HF), ischemic stroke, chronic kidney disease (CKD), and type 2 diabetes (T2D). Genetic association and gene expression summary data 19 20 were obtained from the largest European ancestry GWAS and GTEx v8 for 29 21 tissues that were broadly relevant to the pathophysiology of cardiovascular 22 outcomes included.

#### 23 Results

The genetic evidence supported that lower SBP was universally beneficial, causally associated with reduced risks of all studied outcomes. The association of genetically predicted SBP lowering varied significantly depending on the antihypertensive drug class, revealing heterogeneity in their impact on different health outcomes. Novel MR associations were identified, including protective effects of endothelin receptor antagonists, sGC stimulators, and PDE5 inhibitors against CAD (per 10-mmHg

decrease in SBP, OR range = 0.197 - 0.348) and ischemic stroke (OR range = 0.218
0.686); and sGC stimulators and PDE5 inhibitors against CKD risk (OR range =
0.532 - 0.55). SMR and colocalisation analyses include evidence for *GUCY1A3* and
CAD and MI risk, *KCNH2* with AF risk, and *PDE5A* with CAD risk.

## 34 Conclusions

Our results support potential differential impacts of antihypertensive drug classes on cardiometabolic and renal outcomes, underscoring the potential for personalised therapy. Future research should validate these findings across diverse populations and explore the mechanistic pathways between antihypertensive BP modulation and health outcomes.

## 40 Clinical Perspective

### 41 What is New?

42 This study utilised Mendelian randomisation, summary-based MR, and differential 43 colocalisation analyses to explore the effects of 17 44 antihypertensive drug classes on various cardiometabolic and renal outcomes. 45

Although lower SBP is universally beneficial for reducing risks across all
 outcomes, the effectiveness of SBP lowering varies significantly by
 antihypertensive drug class, showing heterogeneity in their impact on different
 health outcomes.

Newer therapies, including ERAs, PDE5 inhibitors, and sGC stimulators,
 showed significant protective effects across various outcomes, with ERAs
 benefiting AF, CAD, MI, and stroke; PDE5 inhibitors protecting against all

4

outcomes except T2D; and sGC stimulators being effective against CAD, MI,
stroke, T2D, and CKD.

## 55 What are the Clinical Implications?

- Understanding the varying impacts of different antihypertensive drug classes
   on health outcomes can guide more personalised treatment strategies,
   potentially improving patient outcomes.
- These results not only validate the clinical relevance of existing
   antihypertensive therapies but also highlight new therapeutic targets, such as
   *GUCY1A3* and *PDE5A*, for further exploration.
- Future research should focus on validating these results across diverse
   populations to refine hypertension management strategies and implement
   personalised treatment in clinical practice.
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- \_\_\_\_
- 73
- 74

75

## 76 Introduction

Blood pressure (BP) regulation is a complex, multifactorial process influenced by a 77 range of genetic, environmental, and lifestyle factors (1). Hypertension, defined as a 78 79 BP level above a specific threshold associated with an increased risk of cardiovascular outcomes, is similarly multifactorial (2). Current hypertension 80 81 treatment guidelines generally recommend an empirical approach, where the initial 82 treatment involves the use of one or two first-line antihypertensive agents from different pharmacological classes based on the severity of BP elevation (3-5). If BP 83 84 remains uncontrolled, additional agents are sequentially introduced. Given the complexity of hypertension pathophysiology, it remains unclear whether the 85 standardised approach to treatment is the optimal strategy for BP control. The 86 question of whether individually targeted BP treatments can maximise clinical 87 benefits has not been thoroughly explored. 88

89 Randomised clinical trials (RCTs) have established the efficacy of commonly used 90 antihypertensive drugs (6, 7), leading to the perception that the case for 91 personalising therapy is more academic than clinically relevant. Nevertheless, 92 despite regularly updated guidelines and a wealth of clinical evidence, a significant 93 percentage of adults with hypertension continue to have uncontrolled BP despite 94 ongoing antihypertensive therapy (8). This persistent issue suggests that a re-95 evaluation of treatment strategies may be necessary.

There is substantial evidence for intra- and inter-individual variability in BP response to different antihypertensive drugs partially explained by factors such as genetics, age, sex, dietary factors and baseline BP levels (1). Additionally, variability in long-

99 term outcomes has been observed depending on the antihypertensive drug class; for 100 example, ACE inhibitors and ARBs have demonstrated superior efficacy in reducing the risks of heart failure and chronic kidney disease (9, 10). The recent PHYSIC trial, 101 102 employing a randomized repeated cross-over design, further highlighted significant 103 variability in individual BP responses to four commonly used antihypertensive drugs, 104 suggesting that personalised therapy could achieve greater BP reductions (11). 105 However, evidence gaps remain, particularly concerning other antihypertensive drug 106 classes and a broader range of clinically important outcomes, such as coronary 107 artery disease (CAD), stroke, heart failure (HF), atrial fibrillation (AF), chronic kidney disease (CKD), and type 2 diabetes (T2D). Addressing these gaps through 108 109 randomized controlled trials (RCTs) is likely to be both challenging and impractical. Over the last 15 years, genome-wide association studies (GWAS) have provided a 110 111 wealth of genetic data, enabling novel analytical approaches to study the causal effects of risk factors and therapeutic interventions on health outcomes (12). 112 113 Mendelian randomisation (MR) (13), summary-based Mendelian Randomisation 114 (SMR) (14), and colocalisation analyses (15) are powerful tools that leverage genetic variants as instrumental variables to infer causality and elucidate the mechanisms 115 underlying complex traits. By using genetic proxies for BP, MR can elucidate the 116 long-term effects of BP-reducing drug targets on various health outcomes, relatively 117 118 devoid of confounding factors and reverse causation (13). SMR further extends this 119 approach to identify causal effects of gene expression on traits, while colocalisation distinguishes between pleiotropy and shared genetic causation (14, 15). 120 121 In this study, we propose to explore the heterogeneity of responses to a majority of

antihypertensive drugs across a wide range of cardiometabolic and renal outcomes
through an integrative approach combining MR, SMR, and colocalisation analyses.

7

By combining multiple methods along with triangulation of evidence, this study seeks

to strengthen the case for personalised therapy for hypertension, challenging the

126 standardised treatment approach currently advocated in clinical guidelines.

## 127 Methods

- 128 Study design: Our study includes two stages: (i) perform two-sample Mendelian
- 129 randomisation (MR) to explore potential causal effects of SBP reduction and
- 130 antihypertensive drug classes on a range of cardiovascular, diabetic, and renal
- 131 outcomes; (ii) perform summary-based MR and colocalisation to examine if any
- 132 detected drug-disease association is mediated through gene transcription,
- 133 integrating summary data from GWAS and expression quantitative trait loci (eQTL)

## 134 studies (**Figure 1**).

- 135 All data used in this study are publicly available summary data extracted from GWAS
- and eQTL studies, with ethical approval and informed consent from all participants
- 137 being obtained from their original studies.

## 138 Identification of antihypertensive drug classes and their drug target genes

- 139 17 antihypertensive drug classes were identified by reviewing the British National
- 140 Formulary (BNF) (16). These are angiotensin-converting enzyme inhibitors (ACEi),
- 141 angiotensin II receptor blockers (ARBs), calcium channel blockers (CCBs), beta-
- 142 adrenoceptor blockers (BBs), thiazides and related diuretics (TZDs), alpha-
- 143 adrenoceptor blockers, adrenergic neuron blocking drugs, centrally acting
- 144 antihypertensive drugs, loop diuretics, potassium-sparing diuretics (PSDs),
- 145 aldosterone antagonists, renin inhibitors, endothelin receptor antagonists (ERAs),
- 146 phosphodiesterase type 5 (PDE5) inhibitors, soluble guanylate cyclase (sGC)
- 147 stimulators, and vasodilator antihypertensives. An emerging therapy included in our

study is Zilebesiran (17), an investigational RNA interference agent that inhibits the
production of hepatic angiotensinogen, which has shown effectiveness in lowering
BP (**Table S1**).

Pharmacologically active protein targets of each drug class and the corresponding
genes were identified using the Drugbank database. In total, we obtained 57 drug
target genes (**Table S1**).

## 154 Selection of genetic instruments for MR analysis of drug class effects

155 To proxy the effect of antihypertensive drug target perturbation, genetic instruments

were selected as single nucleotide polymorphisms (SNPs) located within 100 kb on

either side of each drug target gene and strongly associated with systolic blood

158 pressure (SBP) at a genome-wide significant level p-value <  $5 \times 10^{-8}$ . Summary

159 statistics for SBP were obtained from a GWAS meta-analysis of 757,601 European-

ancestry participants drawn from the UK Biobank and the International Consortium of

161 Blood Pressure (ICBP) (18).

162 For some drug classes whose protein targets are encoded by different genes,

163 genetic instruments for each gene were combined as a single set of instruments for164 the drug effect analysis (19).

Linkage disequilibrium (LD) clumping at  $r^2 < 0.1$  was conducted to remove highly correlated SNPs. F-statistics were calculated to evaluate the strength of individual genetic instruments (20).

## 168 Selection of genetic instruments for MR analysis of SBP-lowering effects

169 SNPs associated with SBP at a p-value <  $5 \times 10^{-8}$  (18) across the whole genome were

170 selected as genetic instruments for SBP. Due to the large number of SNPs identified,

a more stringent threshold  $r^2 < 0.001$  was used for the clumping to minimise potential 171 bias from LD. The instrument strength was guantified using  $R^2$  and F-statistics (20). 172 Selection of genetic instruments for summary-based MR analysis of drug 173 target gene expression 174 175 Cis-expression quantitative loci (cis-eQTL) were selected as genetic instruments to 176 proxy for the effect of changes in gene expression level. Only cis-eQTL located 177 within 1 Mb window of the gene were considered for the selection. Significant ciseQTL data ( $p < 5 \times 10^{-8}$ ) were obtained from GTEx version 8 (49 tissues, from nearly 178 179 1000 deceased individuals, predominantly European ancestry) (21). The eQTL data 180 is on a scale of 1 unit change in gene expression level per each additional effect allele. 181 For positive control testing and validation, the association of gene expression with 182 SBP were examined - only genes whose expression levels were associated with 183

184 SBP (p < 0.05) were taken forward for the SMR analysis on the outcomes.

## 185 Outcome data

186 Outcomes under this study include CAD, MI, AF, HF, ischemic stroke, CKD and T2D.

187 These outcomes were selected for the study based on their clinical significance and

relevance to hypertension and BP-lowering drug effects (22-25). GWAS summary

data for these outcomes were obtained from the largest GWAS available, with most

190 participants of European ancestry to align with our exposure data (**Table 1**).

### 191 **Two-sample Mendelian randomisation analysis**

192 MR is a form of instrumental variable analysis, which uses genetic variants as

193 proxies to evaluate the potential causal effect of a modifiable exposure on health

194 outcomes. MR relies on three main assumptions: (i) the genetic variant is strongly

195	associated with the exposure; (ii) the genetic variant is not associated with any
196	confounders relating to the association between the exposure and the outcome; (iii)
197	the genetic variant is not associated with the outcome, except through the exposure.
198	In this two-sample MR analysis, genetic variants located in the vicinity of a gene that
199	encodes the BP-lowering drug target were used as instruments to investigate the
200	causal relationship between antihypertensive drugs and the outcomes. Data
201	harmonisation was performed to ensure the variant-exposure association and the
202	variant-outcome association are aligned to the same effect allele. Palindromic
203	variants were not excluded from the analysis. To ensure consistency in genetic
204	variants used across MR analyses, proxies were not used in our study.
205	The inverse-variant weighted (IVW) method was used as the main MR method. MR
206	estimates were presented as odds ratio (OR) for each outcome, with a 95%
207	confidence interval (CI) per 10 mmHg decrease in SBP. This is to reflect the BP-
208	lowering effect of antihypertensive drug classes. To account for multiple testing, a
209	Bonferroni-corrected p-value of 0.0007 (0.05 / 11 (drug classes & SBP) × 7
210	outcomes) was used to detect significant associations; those with a p-value greater
211	than 0.0007 but less than 0.05 were considered nominal associations.
212	The simple median (26), weighted median (26) and MR Egger (27) methods were
213	performed as sensitivity analyses to evaluate the robustness of MR findings to
214	potential bias. These methods have less stringent assumptions compared to the IVW
215	method. Simple median and weight median methods require at least 50% of the
216	genetic variants to be valid to give a robust MR estimate. MR Egger can give a
217	consistent MR estimate of the causal effect when up to 100% of genetic variants are
218	invalid but require the Instrument Strength Independent of Direct Effect (InSIDE)
219	assumption to be satisfied. The InSIDE assumption states that there is no correlation

11

220	between the pleiotropic effects of genetic variants and the variant-exposure
221	association. Additionally, the MR Egger method provides a test, known as the MR
222	Egger intercept test, to detect directional pleiotropy. The deviation of the intercept
223	from zero indicates evidence of directional pleiotropy (27).
224	Negative control outcome MR analysis was performed for the following outcomes:
225	low hand grip strength (28) (48,596 cases; 207,927 controls; European ancestry),
226	myopia (29) (36,623 cases; 419,031 controls; European ancestry), Parkinson
227	disease (30) (15,056 cases, 18,618 proxy cases, 449,056 controls; European
228	ancestry), and heel bone mineral density (31) (583,314 European ancestry
229	individuals). These outcomes are selected as negative controls as they are currently
230	not known to share strong pathological pathways with hypertension.
231	As BP summary data were obtained from a GWAS meta-analysis that adjusted for
232	body mass index (BMI), collider bias might be introduced in the MR analysis. We
233	performed a sensitivity analysis using BP summary data from a UKB GWAS that did
234	not adjust for BMI (32).
235	To explore whether observed associations between antihypertensive drug classes
236	and the outcomes are mediated through their BP-lowering effect, we performed MR
237	analysis to investigate potential causal effects of genetically proxied SBP reduction
238	on the outcomes of interest, leveraging genetic instruments throughout the whole

239 genome.

LD clumping was performed using the TwoSampleMR package in R (33); IVW,

241 weighted median, simple median, and MR Egger were performed using the

242 MendelianRandomization package (version 0.6.0) in R (34).

## 243 Summary-based Mendelian randomisation analysis

244 Summary-based Mendelian randomisation analysis (SMR) is a form of MR analysis 245 that integrates GWAS and eQTL summary data to discover potential causal association of gene expression level with an outcome. Out of 49 tissues in the GTEx 246 v8 (21), we performed the analysis on 29 tissues that are relevant to the 247 pathophysiology of outcomes of interest and mechanism of the antihypertensive 248 drugs. SMR estimate was presented as a beta coefficient with 95% CI per 1 unit 249 250 increase in the expression of the gene in a particular tissue. To account for multiple SMR testing, a Bonferroni-corrected p-value of 0.0001 was used to explore 251 252 significant associations; a p-value greater than 0.0001 but less than 0.05 indicates a nominal association. 253 HEIDI test is integrated into the SMR method to investigate if an observed 254 association between gene expression and the outcome is due to a linkage scenario, 255 256 in which the gene expression level and the outcome do not share a causal variant 257 (14). A  $p_{HEIDI}$  of 0.01 was used as a threshold to indicate a linkage scenario -  $p_{HEIDI}$  < 0.01 indicates the observed association is likely due to a linkage scenario (14, 35). 258 SMR analyses and HEIDI tests were performed using SMR software version 1.3.1. 259 Default settings were used:  $p_{eQTL} < 5 \times 10^{-8}$ , MAF > 0.01, and eQTL that are in very 260 high or very low LD with the top associated eQTL ( $r^2 > 0.9$  or  $r^2 < 0.05$ ) were 261 excluded from the HEIDI test to avoid collinearity (14). 262

## 263 Colocalisation analysis

Colocalisation analysis was performed to investigate if an observed association
between gene expression level and the outcome is due to a shared causal variant.
We used coloc v5.2.1 R package to perform the analysis. Within a particular

13

- 267 genomic region, a Bayesian test was performed to calculate posterior probabilities
- 268 (PP) for five scenarios (15):
- 269 H<sub>0</sub>: There is no variant associated with either trait.
- $H_1$  and  $H_2$ : There is a variant associated with only one of the two traits.
- H<sub>3</sub>: There are distinct causal variants associated with each of the traits.
- 272 H<sub>4</sub>: There is a shared causal variant for both traits.
- A high PP for  $H_4$  indicates a high probability of a shared causal variant for the traits.
- 274 Whereas a high PP for  $H_3$  suggests that the observed association is likely due to a
- 275 linkage scenario. We used default prior settings for the colocalisation analysis:  $p_1 =$

276  $10^{-4}$ ,  $p_2 = 10^{-4}$ ,  $p_{12} = 10^{-5}$ .

## 277 Results

## 278 Genetic instruments

Throughout the entire genome, 454 uncorrelated SNPs ( $r^2 < 0.001$ ) were identified as genetic instruments for SBP (**Table S2**). F-statistics for all of the SNPs were greater than 10, suggesting a low risk of weak instrument bias. Genetic instruments

- accounted for 4.7% of the total variance in SBP.
- 283 By using the predefined selection criteria, ten antihypertensive drug classes have
- genetic instruments for their effects (**Table S3**). These drug classes include AGTi (2
- 285 SNPs), ACEi (1 SNP), CCBs (29 SNPs), BB (7 SNPs), alpha-blocker (1 SNP), loop
- diuretic (4 SNPs), PSD (1 SNP), ERA (1 SNP), PDE5i (5 SNPs), and sGC stimulator
- 287 (6 SNPs). F-statistics for all SNPs were greater than 10 (ranging from 30.48 to
- 288 352.48), which suggests that the risk of weak instrument bias is low.
- 289 MR analysis of genetically proxied SBP reduction

290 Genetically predicted SBP reduction was significantly associated with a reduced risk 291 of all the primary outcomes, with ORs for the outcomes ranging from 0.71 to 0.87 per 10 mmHg decrease in SBP (Fig 2, Table S4). The results obtained from the simple 292 293 median, weighted median, and MR Egger methods were consistent with the primary 294 MR analysis for all the outcomes except for T2D. The MR Egger intercept test indicated evidence of horizontal pleiotropy in the MR analysis of SBP with T2D risk 295 296 (p-value intercept test = 0.0004; MR Egger OR per 10 mmHg decrease in SBP, 1.08, 95% CI, 0.92 - 1.26, p = 0.35) (Table S4). 297

#### 298 MR analysis of antihypertensive drug classes

299 Genetically proxied antihypertensive drugs showed varying associations with cardiovascular outcomes (Fig. 2-3. Table S5). Most drugs were associated with a 300 reduced risk of CAD, with ACEi and alpha-blockers showing nominal association 301 (OR ranging from 0.197 to 0.747 per 10 mmHg decrease in SBP). AGTi, CCB, ERA, 302 303 and PDE5i showed protective effects against ischemic stroke, while there was suggestive evidence for sGC and PSD (OR range = 0.218 - 0.822). BB and sGC 304 were associated with a reduced risk of MI; AGTi, CCB, ERA and PDE5i showed 305 306 nominal associations (OR range = 0.187 - 0.781). For AF risk, we observed protective effects of CCB and BB, and suggestive evidence for loop diuretics, ERA, 307 and PDE5i (OR range = 0.409 - 0.766). For HF, CCB showed a protective effect, 308 while BB and PDE5i showed suggestive evidence of a protective effect (OR range = 309 0.652 - 0.731). sGC and PDE5i were associated with a reduced risk of CKD; 310 311 whereas alpha-blockers showed a nominal association with an increased CKD risk. ACEi, sGC, and PSD were nominally associated with a reduced risk of T2D (OR 312 range = 0.454 - 0.793). Results from the weighted median, simple median and MR 313

Egger methods (where applicable) were consistent with those from the main MR

analysis, with no horizontal pleiotropy detected in the MR Egger intercept test.

316 Negative control outcome analyses did not detect any significant association (Table

**S6, Fig S1**). MR analysis using summary data for SBP obtained from a UKB GWAS

318 gave consistent results with the primary MR analysis (**Table S7**).

## 319 SMR analysis of drug target gene expression

320 Out of 56 genes encoding the protein targets of the antihypertensive drugs, there

321 were 19 genes whose expression levels were associated with SBP in at least one of

322 the 21 tissues under the study (**Table S8, Fig S2**).

SMR was used to examine associations of gene expression levels with the disease 323 324 outcomes across multiple tissues. Eighty-one associations were found across 15 tissues, which passed the HEIDI test. Three associations remain significant after 325 accounting for multiple testing (p < 0.0001) (Fig 3-4, Fig S3-8. Table S9-16). The 326 expression levels of GUCY1A3 (targeted by sGC stimulators) in the tibial artery and 327 *PDE5A* (targeted by PDE5 inhibitors) in the aorta were significantly associated with 328 CAD risk ( $p_{SMR} = 1.74 \times 10^{-06}$ ,  $p_{HEIDI} = 0.345$  for GUCY1A3, and  $p_{SMR} = 9.12 \times 10^{-06}$ , 329  $p_{HFIDI} = 0.338$  for *PDE5A*). We also found a significant signal for the expression of 330 the KCNH2 gene (targeted by BBs) in the brain cerebellum with AF risk (p<sub>SMR</sub> = 331  $6.02 \times 10^{-05}$ , p<sub>HEIDI</sub> = 0.195) (**Fig 3-4**). 332

333 Colocalisation analysis gave a high posterior probability for a shared causal variant

 $(H_4 PP > 80\%)$  for the following pairs: tibial artery *GUCY1A3* eQTL and CAD risk;

tibial artery GUCY1A3 eQTL and MI risk; and tibial nerve KCNH2 and HF risk (Fig 5,

**Table S11)**. For *PDE5A* expression in the aorta and CAD risk, the H<sub>4</sub> posterior

337 probability is 48%, whereas the  $H_3$  posterior probability is 52%. For *KCNH2* 

expression in the brain cerebellum and AF risk, we got a high  $H_3$  posterior probability (99%), suggesting that these traits have distinct causal variants in the gene region (**Table S11**).

## 341 Discussion

342 Our study utilising an integrative approach that combines MR, SMR and

343 colocalization analyses, provides evidence on the effectiveness of 10

344 antihypertensive drug classes across a range of cardiovascular, metabolic, and renal

outcomes. While lower SBP is universally beneficial, with evidence of being causally

346 associated with reduced risks of all studied outcomes, the effect of SBP lowering

347 varied significantly depending on the antihypertensive drug class, revealing

348 heterogeneity in their impact on different health outcomes.

CCBs demonstrated evidence of consistently protective effects across nearly all 349 outcomes, except for T2D where no significant benefit was observed. BBs were 350 351 evidenced to be particularly beneficial in reducing the risks of CAD, MI, AF and HF, though their effectiveness was inconclusive when considering other outcomes. AGTi 352 were evidenced to be generally effective across most outcomes but had a null effect 353 354 on T2D and did not reach statistical significance for HF and CKD. In contrast, ACEi presented mixed results, offering significant protection against CAD and T2D, but 355 showing no effect on AF and MI, with inconclusive results for other outcomes. Alpha-356 357 blockers were associated with a protective effect against CAD but exhibited a detrimental impact on CKD. PSDs showed clear protective effects against stroke and 358 359 T2D, while results for AF and CAD were null, and the effects on MI, HF, and CKD were inconclusive. Loop diuretics were protective against AF, CAD, and MI, had null 360 effect on CKD and inconclusive for other outcomes. Among the newer or emerging 361

17

362 therapies, ERAs were evidenced to show significant protective effects against AF, 363 CAD, MI and stroke. PDE5 inhibitors were protective across all studied outcomes except T2D, sGC stimulators demonstrated protective effects against CAD, MI, 364 365 stroke, T2D and CKD. 366 This study further integrates data from large-scale GWAS and eQTL studies to investigate whether the observed associations are mediated via gene transcription. 367 We employed the SMR method, followed by the HEIDI test and colocalisation 368 369 analysis to distinguish between linkage and true causality. The analyses were performed for 19 genes across 29 tissues that were broadly relevant to the 370 pathophysiology of the outcomes and the mechanism of the antihypertensive drugs. 371 SMR associations, which were corroborated by both HEIDI test and coloc, include 372 GUCY1A3 - CAD risk, GUCY1A3 - MI risk in the tibial artery, and KCNH2 - HF risk in 373 374 the tibial nerve. We also found a significant association between PDE5A in the aorta 375 and CAD risk, and between KCNH2 in the cerebellum and AF risk, but coloc gave a 376 low to moderate posterior probability for a shared causal variant. Our selection criteria for genetic instruments for antihypertensive drug classes in 377 378 two-sample MR is similar to the criteria applied in the previous study by Gill et al (19). Genetic variants were selected as SNPs located within or near the genes 379 (which encode the protein targets of the drugs) and associated with SBP at p < r380  $5 \times 10^{-8}$ . These SNPs were then clumped to a linkage disequilibrium threshold of  $r^2 < 10^{-8}$ . 381 382 0.1 to ensure that the genetic instruments were uncorrelated. Furthermore, for SMR 383 analysis we used significant eQTL for genes encoding the drug-target proteins as proxies for the effects of gene expression levels to evaluate whether the observed 384 MR association is mediated through gene transcription. There is another approach to 385

386 selecting genetic instruments for antihypertensive drugs, which was applied by

18

387 several MR studies (36, 37). In this approach, genetic variants were selected as eQTL for the corresponding gene in any tissue using the GTEx v7. The selected 388 SNPs were further validated by evaluating their association with SBP using a two-389 390 sample MR - SNPs that showed nominal association with SBP (p-value < 0.05) were 391 retained in the main two-sample MR analysis. Using this approach, a recent MR study on atrial fibrillation found a preventative effect of SBP-lowering via alpha-392 393 blockers, beta-blockers, calcium channel blockers, and vasodilators (37). Our current MR study found significant protective effects of beta-blockers and calcium channel 394 395 blockers and suggestive evidence for loop diuretics and vasodilators (ERAs and 396 PDE5 inhibitors). Furthermore, our SMR analysis on AF risk found a significant signal for the expression of the KCNH2 gene (targeted by BB) in the brain 397 398 cerebellum, and nominal signals for this gene in the brain cerebellum hemisphere 399 and tibial nerve.

400 Our study supports the effectiveness of sGC stimulators in reducing the risks of 401 CAD, MI, and CKD. These findings align with previous research highlighting the role 402 of the nitric oxide (NO)-sGC-cGMP pathway in cardiovascular protection (38-40). 403 The GUCY1A3 gene, which encodes an alpha subunit of the sGC complex, has 404 been linked to CAD and MI in large-scale GWAS (38, 39). Our results show that increased GUCY1A3 expression in the tibial artery is associated with lower SBP and 405 406 a reduced risk of CAD and MI, reinforcing the potential of sGC stimulation as a 407 therapeutic strategy for CAD management.

408 PDE5 inhibitors, commonly used for erectile dysfunction and pulmonary

409 hypertension, were also found to have cardioprotective effects (41, 42). Biological

410 plausibility is supported by its known function through inhibition of the breakdown of

411 cGMP, thereby enhancing NO activity, which has been associated with

cardiovascular benefits. Our MR study supports this, showing a causal association
between PDE5 inhibition and reduced risks of CAD and MI. This was corroborated
by SMR findings, which linked increased *PDE5A* expression in the aorta to higher
SBP and increased CAD risk, suggesting a potential role for PDE5 inhibitors in
cardiovascular disease management.

We also observed suggestive associations between KCNH2 gene expression in the 417 418 tibial nerve and HF risk, with colocalisation analysis indicating a shared causal variant. The KCNH2 gene, known for its role in generating repolarising potassium 419 420 currents, has been implicated in long QT syndrome and drug-induced QT prolongation, conditions associated with an increased risk of sudden cardiac death 421 (43). Our findings further support the association of beta-blockers with reduced risks 422 of HF and AF in relation to hypertension, highlighting KCNH2 as a potential target for 423 therapeutic intervention. 424

Our study is the first study to conduct this in-depth investigation of the effects of a 425 wide range of antihypertensive drug classes - at the drug class level as well as the 426 individual target gene expression level - on a broad spectrum of diseases, including 427 cardiovascular, diabetic and renal diseases. The integration of MR, SMR, and 428 429 colocalization analyses allowed us to triangulate evidence and enhance the credibility of our findings. The convergence of MR and SMR results for PDE5 430 inhibition, sGC stimulation, and ACE inhibition underscores the robustness of these 431 432 findings. By corroborating results across different analytical methods, we reduced the likelihood of bias and confounding, thereby strengthening the causal inferences. 433 Our study has limitations. Firstly, as MR estimates the cumulative effect of lifetime 434 exposure to genetic variants, they may differ from the effects obtained from a clinical 435

20

436 intervention such as an antihypertensive treatment. Although the discrepancy 437 suggests that MR estimates may not precisely reflect the effect size of pharmacological intervention, MR still serves as a valuable tool to detect the 438 439 existence and directionality of causal effects. Secondly, some of the drug classes do 440 not have genetic instruments, thus, the study was unable to investigate the potential causal effects of those. Future studies that include a GWAS with a large sample size 441 442 for blood pressure (44) could potentially identify such variants and therefore could provide a more profound understanding of the varying effects of different 443 444 antihypertensive drug classes. Thirdly, tissue misspecification is another limitation of the study, given the limited availability of eQTL data for some specific tissues. eQTL 445 studies with sufficient sample sizes will help alleviate this issue. Finally, summary 446 447 data used in this study was restricted to individuals of European descent, potentially 448 limiting the generalizability of the results to this specific group. The availability of large-scale GWAS datasets from more ethnically diverse populations will allow future 449 450 MR studies to investigate potential ethnic differences.

## 451 Conclusion

Our findings demonstrate the power of integrating MR, SMR, and colocalization 452 analyses to uncover the potential differential effects of various antihypertensive drug 453 classes on a broad spectrum of cardiometabolic and renal outcomes. The 454 heterogeneity observed in drug efficacy across different outcomes underscores the 455 456 potential of personalised antihypertensive therapy. These results not only validate the clinical relevance of existing antihypertensive therapies but also highlight new 457 therapeutic targets, such as GUCY1A3 and PDE5A, for further exploration. Future 458 research should focus on validating these findings in diverse populations and 459

21

460 exploring the mechanistic pathways that link blood pressure regulation to various
461 health outcomes, ultimately paving the way for more personalized and effective
462 hypertension management strategies.

## 463 Acknowledgement

464 Conceptualization: S.P.; Data curation: N.N.L.; Formal analysis: N.N.L.;
465 Methodology: N.N.L., T.Q.B., D.G. and S.P.; Supervision: J.M., D.G. and S.P.; Writing
466 – original draft: N.N.L.; Writing - review & editing: N.N.L., T.Q.B., J.M., D.G. and S.P.

## 467 Sources of Funding

468 SP is supported by the British Heart Foundation Centre of Excellence Award 469 (RE/18/6/34217) and the United Kingdom Research and Innovation Strength in 470 Places Fund (SIPF00007/1). TQBT is supported by a British Heart Foundation 471 Fellowship (FS/MBPhD/22/28005). NNL and SP acknowledge the support provided 472 by the Pontecorvo Chair of Pharmacogenomics endowment.

## 473 Disclosures

474 All authors report no conflict of interest.

475

476

477

478

## 479 Tables

## 480 **Table 1. GWAS used in MR analyses.**

Trait	Population	Sample	Unit	Adjustments
		size		
Systolic	European	757,601	mmHg	Age, age squared, sex, BMI,
blood				genotyping chips,
pressure				antihypertensive medication
(18)				
Atrial	European	1,030,836	log-	Age, sex, study-specific
fibrillation		(60620	transformed	covariates, principal
(45)		cases)	odds	components
Heart	European	977,323	log-	Age, sex, principal
failure (46)		(47309	transformed	components
		cases)	odds	
Coronary	> 95%	1,165,690	log-	Age, sex, study-specific
artery	European	(181,522	transformed	covariates, principal
disease		cases)	odds	components
(47)				
Myocardial	77% European	171,875	log-	Age, sex, study-specific
infarction		(43676	transformed	covariates, principal
(39)		cases)	odds	components
Ischemic	European	1,296,908	log-	Age, sex, study-specific
stroke (48)		(62100	transformed	covariates, principal
		cases)	odds	components

23

	Type 2	European	933,970	log-	Age, sex, study-specific
	diabetes		(80154	transformed	covariates, principal
	(49)		cases)	odds	components
	Chronic	European	480,698	log-	Age, sex, study-specific
	kidney		(41395	transformed	covariates, principal
	disease		cases)	odds	components
	(50)				
481					
400					
482					
483					
484					
485					
-00					
486					
487					
488					
489					
490					
491					
400					
492					
493					
494					

24

#### **Figures** 495

#### 496 Figure 1. Study design

497 SBP, systolic blood pressure; GWAS, genome-wide association study; SNP, single nucleotide 498 polymorphism; eQTL, expression quantitative loci; MR, Mendelian randomization; CAD, coronary 499 artery disease; MI, myocardial infarction; AF, atrial fibrillation; HF, heart failure; CKD, chronic kidney 500 disease; T2D, type 2 diabetes; IVW, inverse variant weighted; (\*) indicates a blood pressure GWAS 501 meta-analysis (18).



502

medRxiv preprint doi: https://doi.org/10.1101/2024.08.22.24312458; this version posted August 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

#### 503 Figure 2-A. MR estimates for the effect of genetically lower blood pressure through

504 the drug target genes of antihypertensive drug classes on the risk of the outcomes. 505

Data were represented as odds ratio (OR) with 95% confidence interval (CI) of the outcome per 10 506 mmHg decrease in systolic blood pressure with risk for the outcomes of interest. OR of less than 1 507 suggests a decreased risk of disease associated with blood pressure lowering treatments, and vice 508 versa. CAD indicates coronary artery disease; MI, myocardial infarction; AF, atrial fibrillation; HF, heart 509 failure; CKD, chronic kidney disease; T2D, type 2 diabetes; AGTi, Angiotensinogen inhibitor; ACEi, angiotensin-converting enzyme inhibitors; CCBs, calcium channel blockers; SBP, systolic blood

- 510
- 511 pressure.



OR per 10-mmHg decrease in SBP (95% CI)

medRxiv preprint doi: https://doi.org/10.1101/2024.08.22.24312458; this version posted August 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

## 513 Figure 2-B. MR estimates for the effect of genetically lower blood pressure through

the drug target genes of antihypertensive drug classes on the risk of the outcomes.

515 Data were represented as effect size with 95% confidence interval (CI) of the outcome per 10 mmHg

decrease in systolic blood pressure with risk for the outcomes of interest. FG, fasting glucose; AGTi,

517 Angiotensinogen inhibitor; ACEi, angiotensin-converting enzyme inhibitors; CCBs, calcium channel

blockers; Other PSDs, potassium-sparing diuretics (not include aldosterone antagonists); ERAs,
 endothelin receptor antagonists; PDE5 inhibitors, phosphodiesterase type 5; sGC; soluble guanylate

520 cyclase; SBP, systolic blood pressure.



OR per 10-mmHg decrease in SBP (95% CI)

**Figure 3. Results from MR, SMR, and colocalization analyses.** Graph A shows MR results for drug classes that have association with the disease risk. Graph B shows SMR results for genes whose expression levels associated with the disease risk at p-value of 0.001; genes were placed at the same vertical point of the drug class that targets their proteins; full SMR results are shown in Fig 4, Fig S3-8. Graph C shows posterior probability for the scenario of distinct causal variants (H3, on the left of the vertical line) and of shared causal variant (H4, on the right). ASc, Adipose Subcutaneous; AdrG, Adrenal Gland; AAo, Artery aorta; Atib, Artery tibial; BCH, Brain Cerebellar Hemisphere; BC, Brain Cerebellum; BFCB9, Brain Frontal Cortex BA9; KC, Kidney Cortex; NTib, Nerve Tibial; Panc, Pancreas; Thy, Thyroid.



#### Figure 4. SMR associations of drug target gene-expression levels with CAD risk.

The x-axis represents the  $\beta$  estimates from SMR analysis, and the y-axis represents the -log10(p<sub>SMR</sub>). The circle, which signifies the corresponding gene, was coloured according to the drug class that targets its protein.  $\beta_{SMR}$  were estimates from SMR analysis per 1 unit increase in the expression of the genes in a particular tissue.  $\beta_{SMR}$  < 0 suggests that an increase in gene expression levels in a particular tissue was associated with a decrease in CAD risk, and vice versa. The blue and orange dashed lines indicate a p-value of 0.05 and a Bonferroni-corrected p-value of 0.0001, respectively. The asterisk indicates HEIDI p-value greater than 0.01; The identifiers for each SMR association circle are the relevant gene name along with the following abbreviations for tissue types: AVO, Adipose Visceral Omentum; ASc, Adipose Subcutaneous; AdrG, Adrenal Gland; AAo, Artery aorta; Atib, Artery tibial, BCaud, Brain Caudate basal ganglia; BCH, Brain Cerebellar Hemisphere; BC, Brain Cerebellum; BCor, Brain Cortex; BFCB9, Brain Frontal Cortex BA9; BNacc, Brain Nucleus accumbens basal ganglia; BPut, Brain Putamen basal ganglia; HAA, Heart Atrial Appendage; HLV, Heart Left Ventricle, KC, Kidney Cortex, MSk, Muscle Skeletal, NTib, Nerve Tibial; Panc, Pancreas; Thy, Thyroid; WB, Whole Blood.



29

Figure 5. Colocalisation of eQTL in tibial artery for *GUCY1A3* and CAD risk. Colocalisation of genetic signal for *GUCY1A3* levels and CAD outcome in the 1-Mb window of the gene. SNPs are coloured according to their LD  $r^2$  with the lead SNP rs72687508.



medRxiv preprint doi: https://doi.org/10.1101/2024.08.22.24312458; this version posted August 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

#### 30

# References

1. Padmanabhan S, Dominiczak AF. Genomics of hypertension: the road to precision medicine. Nat Rev Cardiol. 2021;18(4):235-50.

2. Frohlich ED, Dustan HP, Bumpus FM. Irvine H. Page: 1901-1991. The celebration of a leader. Hypertension. 1991;18(4):443-5.

3. NICE guideline [NG136]. Hypertension in adults: diagnosis and management 28 August 2019 [updated 21 November 2023. Available from:

https://www.nice.org.uk/guidance/ng136.

4. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104.

5. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017

ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115.

6. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-67.

7. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses. J Hypertens. 2015;33(2):195-211.

8. Collaboration NCDRF. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80.

9. NICE guideline [NG106]. Chronic heart failure in adults: diagnosis and management 12 September 2018 [Available from:

https://www.nice.org.uk/guidance/ng106.

10. NICE guideline [NG203]. Chronic kidney disease: assessment and management 25 August 2021 [updated 24 November 2021. Available from: https://www.nice.org.uk/guidance/ng203.

11. Sundstrom J, Lind L, Nowrouzi S, Hagstrom E, Held C, Lytsy P, et al. Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial. JAMA. 2023;329(14):1160-9.

12. Tam V, Patel N, Turcotte M, Bosse Y, Pare G, Meyre D. Benefits and limitations of genome-wide association studies. Nat Rev Genet. 2019;20(8):467-84.

13. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1-22.

14. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48(5):481-7.

15. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10(5):e1004383.

16. Joint Formulary Committee. British National Formulary (online) London: BMJ and Pharmaceutical Press [Available from: http://www.medicinescomplete.com.

Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, et al. 17. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. New England Journal of Medicine. 2023;389(3):228-38.

Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et 18. al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nature Genetics. 2018;50(10):1412-25.

Gill D, Georgakis MK, Koskeridis F, Jiang L, Feng Q, Wei WQ, et al. Use of 19. Genetic Variants Related to Antihypertensive Drugs to Inform on Efficacy and Side Effects. Circulation. 2019;140(4):270-9.

Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, 20. et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Statistical Methods in Medical Research. 2011;21(3):223-42.

Consortium GT. The GTEx Consortium atlas of genetic regulatory effects 21. across human tissues. Science. 2020;369(6509):1318-30.

22. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383(9932):1899-911.

Anderson AH, Yang W, Townsend RR, Pan Q, Chertow GM, Kusek JW, et al. 23. Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study. Ann Intern Med. 2015;162(4):258-65.

Emdin CA, Anderson SG, Woodward M, Rahimi K. Usual Blood Pressure and 24. Risk of New-Onset Diabetes: Evidence From 4.1 Million Adults and a Meta-Analysis of Prospective Studies. J Am Coll Cardiol. 2015;66(14):1552-62.

25. Emdin CA, Anderson SG, Salimi-Khorshidi G, Woodward M, MacMahon S, Dwyer T, et al. Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults. Int J Epidemiol. 2017;46(1):162-72.

Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in 26. Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40(4):304-14.

27. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-25.

28. Jones G, Trajanoska K, Santanasto AJ, Stringa N, Kuo CL, Atkins JL, et al. Genome-wide meta-analysis of muscle weakness identifies 15 susceptibility loci in older men and women. Nat Commun. 2021;12(1):654.

29. Jiang L, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for biobank-scale data. Nat Genet. 2021;53(11):1616-21.

Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang 30. D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091-102.

31. Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for biobank-scale datasets. Nat Genet. 2018;50(7):906-8.

perpetuity. It is made available under a CC-BY 4.0 International license .

32

32. Neale B. Rapid GWAS of Thousands of Phenotypes in the UK Biobank 2020 ſ

33. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife. 2018;7.

34. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46(6):1734-9.

Chauquet S, Zhu Z, O'Donovan MC, Walters JTR, Wray NR, Shah S. 35. Association of Antihypertensive Drug Target Genes With Psychiatric Disorders: A Mendelian Randomization Study. JAMA Psychiatry. 2021;78(6):623-31.

Walker VM, Kehoe PG, Martin RM, Davies NM. Repurposing antihypertensive 36. drugs for the prevention of Alzheimer's disease: a Mendelian randomization study. Int J Epidemiol. 2020;49(4):1132-40.

37. Geurts S, Tilly MJ, Lu Z, Stricker BHC, Deckers JW, de Groot NMS, et al. Antihypertensive Drugs for the Prevention of Atrial Fibrillation: A Drug Target Mendelian Randomization Study. Hypertension. 2024;81(8):1766-75.

Kessler T, Wobst J, Wolf B, Eckhold J, Vilne B, Hollstein R, et al. Functional 38. Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus. Circulation. 2017;136(5):476-89.

39. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1.000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121-30.

Erdmann J, Stark K, Esslinger UB, Rumpf PM, Koesling D, de Wit C, et al. 40. Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature. 2013;504(7480):432-6.

Hutchings DC, Anderson SG, Caldwell JL, Trafford AW. Phosphodiesterase-5 41. inhibitors and the heart: compound cardioprotection? Heart. 2018;104(15):1244-50. 42. Andersson DP, Landucci L, Lagerros YT, Grotta A, Bellocco R, Lehtihet M, et al. Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease. J Am Coll Cardiol. 2021;77(12):1535-50.

Newton-Cheh C, Guo CY, Larson MG, Musone SL, Surti A, Camargo AL, et 43. al. Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study. Circulation. 2007;116(10):1128-36.

Keaton JM, Kamali Z, Xie T, Vaez A, Williams A, Goleva SB, et al. Genome-44. wide analysis in over 1 million individuals of European ancestry yields improved polygenic risk scores for blood pressure traits. Nat Genet. 2024;56(5):778-91.

45. Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nature Genetics. 2018;50(9):1234-9.

Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, et al. 46. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature Communications. 2020;11(1).

Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, et al. Discovery 47. and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nature Genetics. 2022;54(12):1803-15.

48. Mishra A, Malik R, Hachiya T, Jurgenson T, Namba S, Posner DC, et al. Stroke genetics informs drug discovery and risk prediction across ancestries. Nature. 2022;611(7934):115-23.

49. Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat Genet. 2022;54(5):560-72. Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, et al. A catalog of 50. genetic loci associated with kidney function from analyses of a million individuals. Nat Genet. 2019;51(6):957-72.